Synonyms: clone III | Emgality® | galcanezumab-gnlm | LY-2951742 | LY2951742
galcanezumab is an approved drug (FDA (2018))
Compound class:
Antibody
Comment: Galcanezumab (LY2951742) is a monoclonal antibody targeting calcitonin A and B (CALCA a.k.a. α-CGRP and CALCB a.k.a. β-CGRP respectively), whose anti-migraine and analgesic actions can be applied clinically.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent WO2007076336 [1]. |
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes (FDA (2018)) |
Approved drug? | Yes. FDA (2018) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10277 | galcanezumab |
Synonyms ![]() |
clone III | Emgality® | galcanezumab-gnlm | LY-2951742 | LY2951742 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 609 |
Other databases | |
GtoPdb PubChem SID | 310264747 |
Search PubMed clinical trials | galcanezumab |
Search PubMed titles | galcanezumab |
Search PubMed titles/abstracts | galcanezumab |